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Summary
Background Rapid increases in cases of COVID-19 were observed in multiple cities in Iran towards the start of the 
pandemic. However, the true infection rate remains unknown. We aimed to assess the seroprevalence of antibodies 
against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 18 cities of Iran as an indicator of the 
infection rate.
Methods In this population-based cross-sectional study, we randomly selected and invited study participants from the 
general population (from lists of people registered with the Iranian electronic health record system or health-care 
centres) and a high-risk population of individuals likely to have close social contact with SARS-CoV-2-infected 
individuals through their occupation (from employee lists provided by relevant agencies or companies, such as 
supermarket chains) across 18 cities in 17 Iranian provinces. Participants were asked questions on their demographic 
characteristics, medical history, recent COVID-19-related symptoms, and COVID-19-related exposures. Iran Food and 
Drug Administration-approved Pishtaz Teb SARS-CoV-2 ELISA kits were used to detect SARS-CoV-2-specific IgG and 
IgM antibodies in blood samples from participants. Seroprevalence was estimated on the basis of ELISA test results 
and adjusted for population weighting (by age, sex, and city population size) and test performance (according to our 
independent validation of sensitivity and specificity).
Findings From 9181 individuals who were initially contacted between April 17 and June 2, 2020, 243 individuals 
refused to provide blood samples and 36 did not provide demographic information and were excluded from the 
analysis. Among the 8902 individuals included in the analysis, 5372 had occupations with a high risk of exposure to 
SARS-CoV-2 and 3530 were recruited from the general population. The overall population weight-adjusted and test 
performance-adjusted prevalence of antibody seropositivity in the general population was 17·1% (95% CI 14·6–19·5), 
implying that 4 265 542 (95% CI 3 659 043–4 887 078) individuals from the 18 cities included were infected by the end 
of April, 2020. The adjusted seroprevalence of SARS-CoV-2-specific antibodies varied greatly by city, with the highest 
estimates found in Rasht (72·6% [53·9–92·8]) and Qom (58·5% [37·2–83·9]). The overall population weight-adjusted 
and test performance-adjusted seroprevalence in the high-risk population was 20·0% (18·5–21·7) and showed little 
variation between the occupations included.
Interpretations Seroprevalence is likely to be much higher than the reported prevalence of COVID-19 based on 
confirmed COVID-19 cases in Iran. Despite high seroprevalence in a few cities, a large proportion of the population 
is still uninfected. The potential shortcomings of current public health policies should therefore be identified to 
prevent future epidemic waves in Iran.
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Introduction
COVID-19, the disease first reported in Wuhan in the 
Chinese province of Hubei in late 2019, has spread 
and caused high morbidity and mortality worldwide.1 
The spectrum of COVID-19 severity varies widely, from 
asymptomatic infection to severe outcomes including 
organ failure and death.2,3 So far, the main body of 
evidence on population-level infection and fatality rates 
in Iran has been solely based on the severe end of the 
disease spectrum. Thus, in the absence of seroprevalence 
surveys and an unknown proportion of asymptomatic 
cases in the country, the true infection rate of severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 
the virus that causes COVID-19, remains unclear.1,4,5
Articles
474 www.thelancet.com/infection   Vol 21   April 2021
 Biochemistry, Kermanshah 
University of Medical 
Sciences, Kermanshah, Iran 
(E Shakiba PhD); Liver and 
Gastrointestinal Diseases 
Research Center, Tabriz 
University of Medical Sciences, 
Tabriz, Iran (M H Somi MD); 
Microbiology Department, 
Burn & Wound Healing 
Research Center, Shiraz 
University of Medical Sciences, 
Shiraz, Iran (A Emami PhD); 
Hearing Research Center, Ahvaz 
Jundishapur University of 
Medical Sciences, Ahvaz, Iran 
(N Saki MD); Gastroenterology 
and Hepatology Disease 
Research Center, Qom 
University of Medical Science, 
Qom, Iran (A Hormati MD); 
Health Promotion Research 
Center, Zahedan University of 
Medical Sciences, Zahedan, Iran 
(A Ansari-Moghaddam PhD); 
Department of Pharmaceutics, 
Faculty of Pharmacy, 
Mazandaran University of 
Medical Sciences, Sari, Iran 
(M Saeedi PhD); Golestan 
Research Center of 
Gastroenterology and 
Hepatology, Golestan 
University of Medical 
Sciences, Gorgan, Iran 
(F Ghasemi-Kebria MSc); Social 
Determinants of Health Center, 
Urmia University of Medical 
Sciences, Urmia, Iran 
(I Mohebbi PhD); Division of 
Gastroenterology & 
Hepatology, Gastrointestinal & 
Liver Diseases Research Center, 
Guilan University of Medical 
Sciences, Rasht, Iran 
(F Mansour-Ghanaei MD); 
Research Center for Health 
Sciences, Hamadan University 
of Medical Sciences, Hamadan, 
Iran (M Karami PhD); HIV/STI 
Surveillance Research Center 
and WHO Collaborating Center 
for HIV Surveillance, Institute 
for Futures Studies in Health, 
Kerman University of Medical 
Sciences, Kerman, Iran 
(H Sharifi PhD); Digestive 
Disease Research Center, 
Ardabil University of Medical 
Sciences, Ardabil, Iran 
(F Pourfarzi PhD); Kurdistan 
University of Medical Sciences, 
Sanandaj, Iran (N Veisi MSc); 
Social Determinants of Health 
Research Center, Health 
Research Institute, Babol 
University of Medical Sciences, 
Babol, Iran (R Ghadimi PhD); 
Clinical Tuberculosis and 
Epidemiology Research Center, 
National Research Institute of
As recommended by WHO, measuring the extent of 
seropositivity could inform the proportion of individuals 
positive for anti-SARS-CoV-2 antibodies in the population 
and could further indicate the rate of disease transmission 
over time.6,7 Moreover, as the extent of infection in 
a popu lation depends heavily on social interactions and 
popu lation density, assessing the proportion of poten tially 
protected individuals in populations with different levels 
of exposure is crucial.8,9 In most seroprevalence surveys to 
date, the cumulative incidence of infection has been solely 
reported by age group and ethnicity.4,10 However, antibody 
testing of individuals with occupations at high-risk of 
exposure to SARS-CoV-2 because of frequent or high-risk 
social interactions (eg, supermarket employees) might be 
necessary for public health decision making on emergency 
lockdowns or return-to-work policies.9
Iran was one of the first countries to report a SARS-CoV-2 
epidemic with a rapid case increase nationwide.7 As 
of Nov 18, 2020, more than 800 000 confirmed cases 
and 42 000 COVID-19-related deaths have been reported in 
the country.11 The first two COVID-19-related deaths were 
reported in Qom province early in the epidemic.7 Because 
of the high number of cases and increased numbers of 
patients in hospitals, restrictions on mass gatherings 
(eg, restaurant closures) were initiated in February, 2020. 
However, the easing of initial lockdown restrictions in 
early April potentially contributed to the second wave 
of SARS-CoV-2 reported in multiple cities of Iran 
in June, 2020. Therefore, national-level sero prevalence 
studies are urgently needed to provide an indication of the 
proportion of the population who have not yet been 
infected and to plan for future health-care needs.7
In this study, we assessed the seroprevalence of anti-
SARS-CoV-2 antibodies among the general population in 
18 cities of Iran during the first wave of the epidemic. 
Furthermore, we estimated the prevalence rates of anti-
body seropositivity among individuals with a high risk of 
occupational SARS-CoV-2 exposure.
Methods
Study design, population, and sampling
In this population-based cross-sectional study, we used 
serological testing for anti-SARS-CoV-2 antibodies to 
assess the prevalence of SARS-CoV-2 infection in 18 cities 
across 17 provinces in Iran (appendix 2 p 1). The selected 
cities were Gorgan, Babol, Sari, Rasht, Ardabil, Tabriz, 
and Urmia in the northern provinces; Tehran, Mashhad, 
Qom, Esfahan, Hamedan, Sanandaj, and Kermanshah in 
the central provinces; and Ahvaz, Kerman, Shiraz, 
and Zahedan in the southern provinces (figure 1).
We randomly selected and invited study participants 
from the general population and from occupations with a 
Research in context
Evidence before this study
Iran was one of the first countries to report an epidemic 
of severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) infections and saw a rapid increase in cases 
nationwide. However, in the absence of seroprevalence 
studies, the true infection rate in Iran has remained unknown. 
We searched MEDLINE, PubMed, Embase, medRxiv, and the 
WHO Global Research Database for publications on the 
seroprevalence of SARS-CoV-2-specific antibodies, published 
in English, using the search terms “severe acute respiratory 
syndrome coronavirus 2”, “COVID-19”, “seroprevalence”, 
“IgG/IgM antibodies”, to August 30, 2020. To date, most 
seroprevalence studies have not been peer reviewed and 
estimation of the seroprevalence of SARS-CoV-2-specific 
antibodies in individuals employed in occupations 
with a high risk of SARS-CoV-2 exposure has been inadequate. 
Furthermore, in most studies, the overall prevalence estimates 
were not further stratified by geographical areas (eg, cities 
within a county or country) and did not take the potential 
variation of infection rate in different regions into account.
Added value of this study
In this population-based study we assessed the seroprevalence 
of SARS-CoV-2-specific antibodies in 18 cities in Iran. This is 
the first seroprevalence study in the Middle East to report the 
prevalence of anti-SARS-CoV-2 antibodies in the general 
population as well as in individuals employed in occupations 
with a high risk of exposure to SARS-CoV-2. Our findings 
imply that, in the general population, 4 265 542 individuals 
from the included cities were infected by the end of 
April, 2020, and that 1 522 798 (35·7%) infected 
individuals in this population were asymptomatic. 
Seroprevalence estimates of SARS-CoV-2-specific antibodies 
showed heterogeneity across the general populations in 
different cities, ranging from 1·7% to 72·6%. Compared 
with other seroprevalence studies from around the world, 
the seroprevalence estimates in the general population 
of Iran in this study were high.
Implications of all the available evidence
The overall 17·1% seroprevalence rate of SARS-CoV-2-specific 
antibodies across the cities in this study confirms that a large 
proportion of the population in Iran is still susceptible to the 
virus. Public health policies and adequate personal protective 
equipment among front-line workers are therefore needed to 
prevent the potential increase in patient load in hospitals 
across the country and to reduce COVID-19-related morbidity 
and mortality, especially during the second and third waves of 
infection. The similar seroprevalence estimates between 
general and high-risk populations has important public health 
implications, possibly indicating inadequate or low adherence 
to infection control measures, which requires further 
investigation.
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high risk of SARS-CoV-2 exposure (eg, front-line health 
and pharmacy workers, taxi drivers, and cashiers or other 
customer-facing staff) from the cities included in the 
study, without specific inclusion or exclusion criteria (full 
details in appendix 2 p 1). Random selection was achieved 
through a systematic sampling approach, by using a 
random number generator to select the first name on the 
list of possible participants in each sub-population, then 
systematically selecting the next participants (appendix 2 
p 1). The general population sample was selected on the 
basis of individuals’ national identification numbers from 
those registered in the Iranian electronic health record 
system (SIB) in 11 cities and from those registered 
with health-care centres in seven cities. Potential 
participants were contacted by telephone using their 
telephone number(s) recorded in those systems. SIB 
includes demographic characteristics and administrative 
health data for around 72 million of 81 million Iranians 
(coverage >88%), and a similar level of coverage is reported 
for health-care centres. The high-risk population sample 
included individuals who were at an increased risk of 
exposure to SARS-CoV-2 because of close social contact 
with infected individuals through their working environ-
ment. High-risk individuals were selected from lists of 
employees provided by the relevant companies or agencies 
in each city (appendix 2 p 1) and were contacted by phone. 
High-risk occupations comprised front-line physicians 
and nurses, non-front-line health-care workers, pharmacy 
staff, taxi drivers, bank employees, and cashiers of super-
market chains. To increase the rate of participation, testing 
was done at the place of work (eg, bank or super market) 
from which individuals were selected. Written informed 
consent was sought from all individuals before enrolment 
in the study.
The study proposal and protocol were approved by 
the ethics committee of Tehran University of Medical 
Sciences (IR.TUMS.VCR.REC.1399.308).
Procedures
At each collaborating centre, an interviewer asked parti-
cipants a series of questions about their demographic 
characteristics, medical history, recent COVID-19-related 
symptoms, and COVID-19-related exposures. After com-
pletion of the questionnaire, a laboratory technician 
collected 5 mL of venous blood into an EDTA-coated 
micro t ainer. Iran’s Food and Drug Administration-
approved SARS-CoV-2 ELISA kits (Pishtaz Teb, Tehran, 
Iran; catalogue numbers PT-SARS-COV-2.IgM-96 and 
PT-SARS-COV-2.IgG-96) were used to assess the presence 
of SARS-CoV-2-specific IgG and IgM antibodies in serum 
samples. Detailed information on sample collection and 
ELISA kits is provided in the appendix 2 (p 3).
Test validation
The manufacturer-reported sensitivity and specificity of 
the ELISA kits were, respectively, 94·1% and 98·3% for 
the SARS-CoV-2 IgG ELISA kit and 79·4% and 97·3% 
for the SARS-CoV-2 IgM ELISA kit. These values were 
based on samples from 34 patients who had COVID-19 
clinical symptoms and positive RT-PCR results, and 
111 serum samples collected and stored at –20°C before 
the SARS-CoV-2 pandemic.
We independently validated the accuracy of the ELISA 
kits using serum samples (collected within 2–4 weeks 
of symptom onset) from 154 patients with RT-PCR-
confirmed COVID-19 and 110 serum samples collected 
2 years before the pandemic that were stored in the 
Digestive Diseases Research Institute biobank (scenario 1; 
appendix 2 p 5). Among the 154 samples positive for 
SARS-CoV-2 on RT-PCR, 103 samples tested positive for 
either IgG (94 [61%]) or IgM (79 [51%]) with the ELISA 
kits, corresponding to a collective sensitivity of 66·9% 
(95% CI 58·9–74·2%). 108 of 110 pre-COVID-19 samples 
tested negative for both IgG and IgM SARS-CoV-2-specific 
anti bodies, corresponding to a collective speci ficity of 
98·2% (95% CI 93·6–99·8). However, as a sensitivity 
analysis, we combined manu facturer’s data with our data 
(188 positive samples and 221 negative samples in total; 
scenario 2; appendix 2 p 5). Combining the manufacturer’s 
Figure 1: Seroprevalence of severe acute respiratory syndrome coronavirus 2 in the general population in 
each city included in the study
The area of each spot on the map is proportional to the seroprevalence in that city. Full data are provided in 
figure 3 and appendix 2 (p 7). Northern provinces: Gorgan, Babol, Sari, Rasht, Ardabil, Tabriz, Urmia. Central 
provinces: Tehran, Mashhad, Qom, Esfahan, Hamedan, Sanandaj, Kermanshah. Southern provinces: Ahvaz, 





































476 www.thelancet.com/infection   Vol 21   April 2021
data with our data yielded a sensit ivity of 71·8% 
(64·8–78·1) and a specificity of 98·2% (95·4–99·5). The 
estimated perfor mance of the kits in scenario 1 was used 
as the primary test characteristic in this study. The 
scenario 2 test per formance was then used to adjust the 
prevalence rates, which were later compared with 
the scenario 1 test-adjusted estimates.
Covariates
Demographic variables included age, sex, and city of 
residence. A comorbid state was defined as presence 
of at least one of the following self-reported medical 
conditions: heart disease, hypertension, lung disease, 
asthma, dia betes, fatty liver disease, cirrhosis, hepatitis B, 
hepatitis C, autoimmune hepatitis, HIV, kidney disease, 
thalassaemia, haemophilia, dementia, multiple sclerosis, 
malignancy, infla mmatory bowel disease, and history 
of organ trans plantation. COVID-19-related symptoms 
included cough, fever, chills, anosmia, sore throat, head-
ache, shortness of breath, diarrhoea, conjunctivitis, 
weakness, myalgia, arthralgia, altered level of conscious-
ness, and chest pain, experienced during the 12 weeks 
preceding questionnaire completion. On the basis 
of self-reported symptoms, parti cipants were further 
cate gorised as asymptomatic, pauci symptomatic (one 
to three symp toms), or symptomatic (four or more 
symptoms).
Statistical analysis
The sample size needed to estimate prevalence in 
the study was calculated to be 9057 on the basis of a 
1% margin of error, a seroprevalence rate of 15%, a type I 
error rate of 0·05, and a design effect of 1·85. The 
required sample size in each city was proportional to 
each city’s population relative to the total population of 
all cities included. Detailed information on sample size 
calculation is provided in appendix 2 (p 1).
Baseline characteristics were described separately for 
each city. The population seroprevalence of SARS-CoV-2-
specific antibodies was estimated for the overall general 
population, the general population by city, the overall and 
high-risk populations by occupation type, the high-risk 
population by city, and all individuals (ie, irrespective 
of antibody positivity) who completed the symptom 
questionnaire.
To assess the seroprevalence of SARS-CoV-2-specific 
antibodies in the general population, we first estimated 
the overall crude frequencies of positive tests, stratified 
by age and sex, as a proportion of the total sample size for 
the general population. This crude prevalence was then 
weighted for age, sex, and the population size of each 
city using the 2016 population and household census 
in Iran. Finally, the weighted estimate of prevalence was 
adjusted for test performance as reported in scenario 1 
and scenario 2.
To assess the seroprevalence of SARS-CoV-2-specific 
antibodies in the high-risk population, we reported the 
crude and test performance-adjusted prevalence of SARS-
CoV-2 antibody positivity in the high-risk groups separately 
for each city. The overall crude prevalence, weighted by city 
population, and test performance-adjusted prevalence of 
SARS-CoV-2-specific antibodies were then estimated for 
the high-risk population by occupation type.
The overall crude prevalence and test performance-
adjusted prevalence of SARS-CoV-2 antibody positivity 
for those with self-reported COVID-19-related symptoms 
were assessed.
95% CIs for unweighted seroprevalence were esti-
mated using exact binomial models and a bootstrap 
method was used to construct the 95% CIs for weighted 
and adjusted estimates.4,12 All statistical analyses were 
done with STATA software (version 12). The statistical 
approach used for population weighting, test perfor-
mance adjustment, and the bootstrap method is detailed 
in appendix 2 (pp 1, 3).
Role of the funding source
The sponsor of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to all 
the data in the study and had final responsibility for the 
decision to submit for publication.
Results
Among 9181 individuals who were contacted across 
18 cities (total population 25 061 939), all individuals 
initially agreed to participate in the study (telephone 
response rate 100%). However, 243 (2·6%) individuals 
refused to provide blood samples at the participation 
centres and were excluded. 36 individuals did not provide 
their demographic information, including age, and were 
also excluded. Of the 8902 individuals included in the 
analysis (figure 2), 1157 (13·0%) participants did not 
complete the questions on COVID-19-related symptoms 
and 1095 (12·3%) did not complete the comorbidity 
questionnaire. Among the 8902 individuals included in 
the analysis, 5372 (60·3%) had occupations with a high 
Figure 2: Study profile
3709 general population
9181 invited
3530 included in general
           population analysis
179 excluded from analysis
162 blood sample not
         provided
17 age not provided
5472 high-risk population
5372 included in high-risk
           population analysis
100 excluded from analysis
81 blood sample not
       provided
19 age not provided
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risk of exposure to COVID-19 and 3530 (39·7%) were 
recruited from the general population. The first date of 
data collection was April 17, 2020, in Tehran, and the last 
date was June 2, 2020, in Zahedan. In 14 cities the data 
collection was finalised by April 30, 2020.
Table 1 shows the demographic characteristics of 
participants by city. Overall, 5059 (56·8%) participants 
were men, most were aged 30–39 years (2995 [33·6%]) or 
40–49 years (2612 [29·3%]), 2220 (28·3%) of 7843 with 
available data had at least one comorbid condition, and 
2642 (30·6%) of 8635 reported recent contact with a 
person confirmed to have COVID-19.
494 individuals tested positive for SARS-CoV-2-specific 
IgG or IgM antibodies with the ELISA kits in the general 
population, resulting in a crude seroprevalence of 
14·0% (exact binomial 95% CI 12·9–15·2; table 2). After 
weighting the sample by age, sex, and city population 
size, and adjusting for test performance, the popul ation 
weight-adjusted and test-adjusted seroprevalence was 
17·1% (14·6–19·5). The seroprevalence estimate for 
the general popu lation implies that 4 265 542 (95% CI 
3 659 043–4 887 078) indi viduals from the 18 cities in the 
study were infected by the end of April, 2020.
The highest age-stratified seroprevalence was observed 
in individuals aged 60 years or older (population 
weight-adjusted and test-adjusted prevalence 29·2% 
[21·4–37·5]; table 2). Among 867 individuals with at least 
one comor bid condition, the test-adjusted prevalence 
was 22·4% (18·0–27·7). Finally, the population weight-
adjusted and test-adjusted seroprevalence estimate in 
Population size Sex Age, years Comorbid conditions Contact with COVID-19 
patients
Total Sample Male ≤19 20–29 30–39 40–49 50–59 ≥60 No Yes (≥1) No Yes


































































































































































































































































































































































































































Data are n, n (%), or n/N (%).
Table 1: Baseline characteristics of study participants by city
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individuals who reported a contact with a person with 
confirmed COVID-19 (30·8% [22·7–39·3]) was consi-
derably higher than that in individuals without such 
contact (14·0% [11·8–16·3]).
In the general population, in an analysis stratified by 
city, the highest population weight-adjusted and test-
adjusted seroprevalence estimates were in the cities of 
Rasht (72·6% [53·9–92·8]), Qom (58·5% [37·2–83·9]), 
Gorgan (43·9% [31·4–58·3]), and Babol (22·4% 
[11·9–35·1]; figures 1, 3; appendix 2 p 7).
Among the 5372 individuals in the high-risk popul ation, 
819 individuals tested positive for SARS-CoV-2-specific 
IgG or IgM antibodies (figure 3). The overall popu lation 
weight-adjusted and test-adjusted sero prevalence was 
20·0% (18·5–21·7; table 3). Similarly to the general popu-
lation, the highest test-adjusted pre valence estimates in 
high-risk populations were in Rasht, Qom, Gorgan, and 
Babol (figure 3; appendix 2 p 8).
In general, the population weight-adjusted and test-
adjusted prevalence in the high-risk population did not 
show any considerable variation among different occupa-
tional groups, ranging from 18·0% (14·6–21·6) in non-
front-line health-care workers to 22·0% (17·1–26·8) in 
cashiers of supermarket chains (table 3).
7745 (84·7%) individuals responded to the COVID-19-
related symptoms questions in the questionnaire 
(appendix 2 p 9). Overall, the prevalence of antibody 
seropositivity among individuals with symptoms was 
considerably higher than that in individuals with no 
symptoms. The highest test-adjusted prevalence esti-
mates were in the 608 individuals with self-reported 
anos mia (75·0% [68·8–81·2]) and the 716 individuals 
with fever (60·8% [55·3–66·5]).
The test-adjusted prevalence increased in propor tion 
to the number of self-reported COVID-19 symp toms: 
14·1% (12·5–15·8) in asymptomatic individuals, 20·1% 
(17·8–22·6) in paucisymptomatic individuals, and 43·3% 
(39·6–47·1) in symptomatic individuals (appendix 2 p 9).
1164 (15·0%) of the 7745 who responded to the ques-
tions on COVID-19-related symptoms tested positive for 
SARS-CoV-2 (appendix 2 p 10). Among 1164 antibody-
positive individuals, 416 (35·7%) did not experience 
any COVID-19-related symptoms, suggesting that 
an estimated 1 522 798 (1 306 278–1 744 686) individuals 
infected before the end of April were asympto matic in 
the total populations of the 18 cities in the study.
Because of the higher test sensitivity (71·8%) in the 
scenario 2 test performance, the scenario 2 test-adjusted 
prevalence estimates were lower than the scenario 1 
estimates. However, the observed trends for estimated 
prevalence rates were consistent between the two test 
performance scenarios in all the analyses (appendix 2 
pp 3–6).
Discussion
In this population-based cross-sectional study, the 
seroprevalence of SARS-CoV-2-specific antibodies was 
estimated in 18 cities with high population densities from 
the north, centre, and south of Iran, and it was higher 
than previous reports from Iran and other countries. In 
a study in Guilan province in Iran, the test-adjusted 
seroprevalence was 33% among the five included 
Sample size, n Seropositive 
participants, n
Seroprevalence, %
Crude Weighted* Adjusted for test 
scenario 1
Adjusted for test 
scenario 2
Total 3530 494 14·0% (12·9–15·2) 12·9% (11·3–14·5) 17·1% (14·6–19·5) 15·8% (13·6–18·2)
Sex
Male 1795 244 13·6% (12·0–15·3) 12·5% (10·5–14·7) 16·5% (13·4–19·9) 15·3% (12·5–18·5)
Female 1735 250 14·4% (12·8–16·2) 13·2% (11·1–15·3) 17·5% (14·3–20·8) 16·3% (13·3–19·3)
Age, years
≤19 140 15 10·7% (6·1–17·0) 11·8% (5·1–19·3) 15·4% (5·1–26·9) 14·3% (4·8–25·0)
20–29 470 44 9·4% (6·9–12·4) 7·4% (4·9–10·4) 8·7% (4·7–13·2) 8·1% (4·4–12·3)
30–39 992 117 11·8% (9·8–14·0) 12·1% (9·4–15·1) 15·8% (11·7–20·4) 14·7% (10·9–19·0)
40–49 937 141 15·0% (12·8–17·5) 14·1% (11·3–16·9) 18·9% (14·6–23·2) 17·6% (13·6–21·6)
50–59 590 87 14·7% (12·0–17·9) 15·7% (12·2–19·5) 21·4% (16·0–27·2) 19·9% (14·9–25·3)
≥60 401 90 22·4% (18·5–26·8) 20·8% (15·8–26·2) 29·2% (21·4–37·5) 27·1% (19·9–34·8)
Comorbidity
Yes 867 156 18·0% (15·5–20·7) 16·4% (13·5–19·8) 22·4% (18·0–27·7) 20·8% (16·8–25·8)
No 1971 257 13·0% (11·6–14·6) 12·7% (10·7–14·9) 16·8% (13·7–20·1) 15·6% (12·8–18·7)
Contact with confirmed COVID-19 patients
Yes 601 122 20·3% (17·2–23·7) 21·8% (16·6–27·4) 30·8% (22·7–39·3) 28·6% (21·1–36·5)
No 2717 343 12·6% (11·40–13·9) 10·9% (9·5–12·4) 14·0% (11·8–16·3) 13·0% (11·0–15·2)
Seroprevalence data are % (95% CI). *Weighted by age, sex, and city population. When a variable was stratified it was removed from the weights.
Table 2: Seroprevalence of severe acute respiratory syndrome coronavirus 2-specific IgG and IgM antibodies in the general population
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counties (Rasht, Anzali, Lahijan, Astara, and Roudbar), 
and the population weight-adjusted seroprevalence 
in Rasht county was 24%.7 By compa rison, the population 
weight-adjusted seropre valence in the general population 
for Rasht city in our study (49·1%; appendix 2 p 7) was 
considerably higher. The observed difference between 
estimates might be related to different study designs and 
sampling methods (household vs indi vidual level) and the 
fact that, in our study, individuals were solely recruited 
from Rasht city and not the entire county. Moreover, 
the observed variation in prevalence estimates among 
included cities in this study could be explained by the fact 
that epidemic protocols were initiated far earlier in some 
cities than others.7,10 For instance, Qom and Guilan were 
the first and second provinces to report increased numbers 
of cases early in the epidemic,7 which might have been 
related to the ongoing trading relationships with Wuhan, 
China, in January, 2020.
Our overall seroprevalence estimate of 17·1% (adjusted 
for population weighting and test performance) was also 
higher than reported US estimates from Santa Clara 
(2·8%),4 New York state (14·0%),10 and Los Angeles 
(4·1% [unweighted pro portion of individuals positive for 
IgG or IgM anti bodies]),13 and also from Spain (5·0%).14 
The higher sero prevalence estimates in our study might be 
explained by the timing of epidemic initiation in Iran. 
Because Iran was among the first countries that reported 
a SARS-CoV-2 epidemic—earlier than the USA and 
European countries—a greater proportion of the Iranian 
population might have been exposed to the virus 
during the same time period. Furthermore, the higher 
sero prevalence estimates in our study could be partly 
related to test characteristics and the low sensitivity of our 
test compared with tests that were used in other countries. 
However, as the overall crude seroprevalence estimate 
among the general population (ie, 14·0%) in our study was 
still considerably higher than seroprevalence esti mates in 
countries such as Spain, the observed difference between 
countries is more likely to be related to epidemic conditions 
and the applied health regulations in each region than to 
test characteristics.14
Consistent with previous reports,4,7,10,13 we found a sub-
stantial difference between the officially reported number 
of confirmed COVID-19 cases and the sero prevalence-
based case estimate. Although the total number of reported 
cases in Iran is currently more than 800 000 individuals, 
our estimate of about 4 265 542 indi viduals infected by the 
end of April, 2020, suggests that the preliminary SARS-
CoV-2 ascertainment rate of 0·6% and the number of cases 
estimated from simulation studies have underestimated 
the epidemic conditions in Iran.4,15–18 Furthermore, 
consistent with a previous meta-analysis, we found that 
35·7% of seropositive indi viduals in our study were 
asymptomatic, representing about 1 522 798 individuals.19 
These findings emphasise the importance of prevention 
strategies such as physical distancing (ie, maintaining a 
distance of >1·5 m from other individuals) and use of face 
masks to further protect the general population from 
SARS-CoV-2 community transmission.
As stated by WHO and shown in a few other studies, 
because of frequent or close social interactions and the 
possibility of asymptomatic transmission, the risk of 
SARS-CoV-2 transmission in certain occupations might 
be increased.9,20–22 However, consistent with another 
seroprevalence study from Guilan province in Iran, the 
seroprevalence estimates in our study did not vary 
Figure 3: Seroprevalence of severe acute respiratory syndrome coronavirus 2 in general populations and 
high-risk populations by city
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by occupation.7 The similar sero prevalence estimates 
between general population and high-risk groups observed 
in our study might be explained by a low compliance of 
the general population with applied health regulations 
(eg, physical distancing), and by inadequate personal 
protective equipment, including medical devices, in high-
risk occupational environments such as hospitals.20–22 
Therefore, the type of occupation could meaningfully 
contribute to the elevated risk of SARS-CoV-2 exposure 
if infection control measures were effectively applied 
to the general population. In the case of insufficient 
prevention strategies, most people would have a high risk 
of exposure outside of their working environment, 
essentially nullifying any safety precautions applied there.
To our knowledge, this is the first multicentre sero-
prevalence study in Iran to report the seroprevalence of 
anti-SARS-CoV-2 antibodies in the general population 
and in individuals employed in occupations with a high 
risk of exposure across 18 cities. In this study, the overall 
prevalence estimates were adjusted not only for sex, 
age, and city population, but also for test performance 
using different scenarios. Despite these strengths, our 
study has some limitations that should be noted. 
First, individuals with a history of COVID-19 symptoms 
might be more willing to participate in the study, 
resulting in an inflated proportion of individuals with 
positive tests and overestimated prevalence. However, 
because participants were randomly selected from the 
population and the response rate to the first study invite 
was high, the potential effect of this limitation on our 
findings is expected to be low. Second, the Pishtaz Teb 
SARS-CoV-2 ELISA kits were not fully assessed before 
this study and required further validation. Additionally, 
the sensitivities of the tests were lower than those of 
tests used in other countries.14 To address these 
limitations, we did additional testing to assess the 
test performance under monitored conditions and 
adjusted all the sero prevalence estimates for the test 
characteristics. Third, in a few cities, such as Tehran, 
because of a strict lock down during the data collection 
period, we could not recruit participants from some 
high-risk occupations (eg, pharmacy workers). There-
fore, the number of samples was not comme nsurate 
with the population of those cities. To resolve this issue 
and achieve the required overall sample size, more 
individuals from the high-risk populations of cities with 
less strict lockdown policies were recruited. However, 
because of the smaller sample sizes in the cities with 
strict lockdowns, the estimates for individual cities 
should be interpreted with caution.
In conclusion, the findings of this study imply that 
prevalence of seropositivity is likely to be much higher 
than the reported prevalence rates based on confirmed 
COVID-19 cases in Iran. Despite the high seroprevalence 
estimates in a few cities, the low overall prevalence esti-
mates highlight the fact that a large proportion of the 
population in Iran is still uninfected. The similar sero-
prevalence estimates across high-risk occupations in this 
study could indicate that the currently applied infection 
control measures might be inadequate or not appro priately 
adhered to or enforced. As such, there is an urgent need 
for public health policies and adequate personal protective 
equipment among front-line workers to prevent the 
potential increase in patient load in hospitals across the 
country, especially during the second wave of infection.23
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1245 209 16·8% (14·8–19·0) 15·9% (13·9–18·0) 21·6% (18·6–24·9) 20·1% (17·3–23·1)
Non-front-line 
health-care workers
1156 162 14·0% (12·1–16·1) 13·5% (11·3–15·9) 18·0% (14·6–21·6) 16·8% (13·6–20·1)
Pharmacy employees 620 101 16·3% (13·5–19·4) 15·5% (12·5–18·6) 21·0% (16·5–25·8) 19·5% (15·3–24·0)
Taxi drivers 718 101 14·1% (11·6–16·8) 14·1% (11·4–16·9) 18·8% (14·7–23·2) 17·5% (13·7–21·6)
Cashiers of 
supermarket chains
753 110 14·6% (12·2–17·3) 16·1% (12·9–19·2) 22·0% (17·1–26·8) 20·5% (15·9–24·9)
Bank employees 880 136 15·5% (13·1–18·0) 14·2% (12·1–16·5) 19·1% (15·8–22·6) 17·7% (14·7–21·0)
Overall high-risk 
population
5372 819 15·3% (14·3–16·2) 14·9% (13·8–16·0) 20·0% (18·5–21·7) 18·6% (17·2–20·2)
Seroprevalence data are % (95% CI). *Weighted by city population size.
Table 3: Seroprevalence of severe acute respiratory syndrome coronavirus 2-specific IgG and IgM antibodies in high-risk populations
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appendices) can be shared with investigators whose proposed use of the 
data has been approved by the independent review committee of Tehran 
University of Medical Sciences and Digestive Diseases Research Institute. 
Data can be provided for individual participant data meta-analysis or other 
projects comparing the seroprevalence estimates in different regions. 
The proposals should be directed to the corresponding author at 
dr.reza.malekzadeh@gmail.com. To gain access, data requesters will need 
to sign a data access agreement, confirmed by RM as the senior author of 
the manuscript and the project leader.
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